Purine nucleotide biosynthesis pathway

The **purine nucleotide biosynthesis pathway** is a highly conserved, energy-intensive metabolic pathway found in all domains of life. It is responsible for the de novo synthesis of purine nucleotides, primarily adenosine monophosphate (AMP) and guanosine monophosphate (GMP), from small molecules including amino acids (glycine, glutamine, aspartate), tetrahydrofolate derivatives, and carbon dioxide. The pathway begins with ribose 5-phosphate, which is converted to 5-phosphoribosyl-1-pyrophosphate (PRPP), then via a series of around ten sequential enzymatic steps forms inosine monophosphate (IMP), the precursor for AMP and GMP. The pathway is regulated through feedback inhibition by its end products and is especially active in rapidly proliferating cells due to a high demand for nucleic acid synthesis. Several enzymes in this pathway are recognized as therapeutic targets in diseases such as cancer, autoimmune disorders, and gout. **Important caveat**: The entry "Purine nucleotide biosynthesis pathway" is not a standard molecular target, but rather a collection of targets (enzymes). When drug development or biological annotation is required, a specific enzyme such as "Inosine monophosphate dehydrogenase" or "PRPP amidotransferase" should be specified. The pathway concept is too broad to map directly to a canonical drug or biomarker target.

Other names

Purine biosynthesisDe novo purine nucleotide synthesisDNPNB pathway

Inhibition of de novo purine synthesis enzymes reduces cell proliferation (especially lymphocytes) Antagonism of nucleotide incorporation into nucleic acids (e.g., via purine analogs)